News

ITM and TerThera Forge Alliance for Terbium-161 Supply

ITM and TerThera Forge Alliance for Terbium-161 Supply

Strategic Supply Agreement for Terbium-161

In a significant move for the radiopharmaceutical industry, ITM Isotope Technologies Munich SE (ITM) and TerThera BV have signed a pivotal supply agreement for non-carrier-added (n.c.a.) Terbium-161 (Tb-161). This partnership aims to harness the potential of Tb-161, a novel medical radioisotope, in the development of advanced cancer therapies.

Enhancing Radiopharmaceutical Therapies

As the fields of oncology and radiopharmaceuticals evolve, the demand for effective treatment options grows. ITM, a prominent player in the biotech landscape, is focused on delivering cutting-edge innovations to clinicians and patients. With the supply agreement with TerThera, ITM can further enhance its pipeline of Tb-161-based therapies, which are currently under clinical investigation for various cancer types.

Why Terbium-161?

Terbium-161 presents a unique profile in terms of its emission characteristics. Similar to Lu-177, it emits medium-range beta particles and shares a comparable half-life. However, what sets Tb-161 apart is its additional emissions of low-energy Auger and internal conversion electrons. This capability allows for highly localized radiation that targets isolated cancer cells and micro-metastases with reduced collateral damage to healthy tissues.

Statements from Leadership

Dr. Andrew Cavey, CEO of ITM, emphasized the significance of this collaboration, stating, "Driving innovation across isotopes, targeting molecules, and cancer indications keeps ITM at the forefront of the rapidly evolving radiopharmaceutical industry. We see strong potential in Terbium-161 as a critical new isotope for targeted therapy, allowing us to make meaningful advances for patients living with cancer."

Commitment to Quality and Safety

Under the terms of the newly minted agreement, TerThera is tasked with delivering GMP-compliant Tb-161 to ITM. Philippe van Overeem, CEO of TerThera, noted, "As the industry interest in Terbium-161 grows, a secure and sustainable supply of this radionuclide is essential. ITM stands as a true innovator in the radiopharmaceutical field, and we look forward to collaborating with them to bring this promising isotope to patients in need." This commitment ensures that the treatments developed in this partnership will meet the highest standards of quality and safety.

Transforming Cancer Treatment

The implications of this agreement extend beyond mere supply logistics. By incorporating Tb-161 into their therapy development, ITM aims to leverage the unique properties of this isotope to unlock new avenues for treating patients with hard-to-treat tumors. The company’s ongoing precision oncology initiatives include multiple Phase 3 studies, demonstrating a robust effort to utilize high-quality radioisotopes combined with innovative targeting molecules.

Future Prospects

With a dedication to improving clinical outcomes, ITM is on a mission to enhance the quality of life for cancer patients worldwide. The collaboration with TerThera will add a compelling component to their offering, supporting the advancement of targeted radiopharmaceutical treatments. As ITM builds upon its established global network and two decades of expertise, the partnership is poised to contribute significantly to the future of oncological therapies.

About ITM and TerThera

ITM is committed to delivering innovative radiopharmaceutical therapeutics and diagnostics, focusing on the unmet needs of cancer patients and their treatment. By emphasizing excellence in the development, production, and global supply of medical radioisotopes, ITM remains at the forefront of precision oncology.

TerThera, based in the Netherlands, is a dedicated player in radionuclide production. With decades of experience in nuclear medicine, the team is focused on making their innovative Terbium-161 available for clinical use. Their ongoing efforts to establish GMP production facilities in Europe, the USA, and Asia highlight the company’s commitment to meeting global radionuclide demands.

Frequently Asked Questions

What is the purpose of the agreement between ITM and TerThera?

The agreement focuses on supplying non-carrier-added Terbium-161 to support ITM’s development of advanced radiopharmaceutical therapies for cancer.

What are the benefits of Terbium-161 in cancer treatment?

Terbium-161 offers unique emissions that allow for targeted radiation to cancer cells, minimizing damage to surrounding healthy tissues.

Who are the key figures mentioned in the agreement?

Dr. Andrew Cavey, CEO of ITM, and Philippe van Overeem, CEO of TerThera, are two notable leaders involved in this initiative.

How does ITM intend to utilize the Tb-161 isotope?

ITM plans to incorporate Tb-161 into its pipeline of cancer therapies, which are currently in various stages of clinical trials.

What is the overall mission of ITM and TerThera?

Both companies share a commitment to innovation in radiopharmaceuticals, aiming to enhance patient outcomes and quality of life through advanced treatments.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Dr. Kumar Joins Florida Cancer Specialists Team

Updated Category News Views 47

Welcoming a New Oncology Specialist to Bradenton What does a small but mighty addition mean for cancer care in Bradenton, Florida? Well, it feels like a big win for the locals. Dr. Vinod Kumar is the latest name to join the ranks of the Florida Cancer Specialists & Research Institute (FCS) at the Bradenton Cancer Center. With years under his belt in medical oncology and...

Continue Reading
Medtronic's Bold Move to Own Carotid Market Full-Scale

Updated Category News Views 64

When a giant like Medtronic makes a move, you can bet investors take notice, and this latest acquisition is no exception. They’re reaching into their deep pockets to acquire Contego Medical, a company shaking up the world of carotid artery disease treatments. It’s a tactical strike to solidify their leadership in cardiovascular solutions. Medtronic's Bet on Innovation...

Continue Reading
Main Capital Partners Backs TaskRay: Salesforce Expansion

Updated Category News Views 18

Investing in Transformation Main Capital Partners has thrown in with TaskRay, joining hands with Cloud Coach and JustOn to shake up customer delivery on Salesforce. These three are cooking up an ambitious AI-driven platform that's gunning to streamline from project management to financial operations. Main's stepping into this mix with a mindset that aligns with over 800...

Continue Reading
Waterfall Backs $48M Loan for Disney-area Hotel Upgrade

Updated Category News Views 15

A $48 Million Shot in the Arm for Portofino Inn Old-school Anaheim just got a real estate shake-up. Waterfall Asset Management's decision to lend a hefty $48 million to Dynamic City Capital (DCC) is more than just a financial move—it's a bet on tourism's bedrock, Disneyland. They're sinking this cash into the Portofino Inn & Suites, located a stone's throw from the...

Continue Reading
Championing Change: USTA Mid-Atlantic Gala's Impact

Updated Category News Views 398

A Night to Remember: USTA Mid-Atlantic's Gala Who would've thought tennis could wield such transformative power? This ain't your average sport gala. Last Saturday, a crowd of over 300 gathered at the Ritz-Carlton Tysons Corner for the USTA Mid-Atlantic Foundation's 2026 Tennis Creates Gala. Hosted by the formidable Malika Andrews, this event wasn't just a fancy...

Continue Reading
Caladan Partners with Anchorage for Stronger Trading

Updated Category News Views 35

Caladan and Anchorage Unite for Asset Growth Man, partnerships might just be the secret sauce we never know we need until it’s on our plate. It's a fresh day in digital trading, and Caladan just shook things up by teaming up with Anchorage Digital, bolstering their trading and settlement capabilities to satisfy the big players. If there's one thing that's hot as a...

Continue Reading
ICCSD in Beijing: AI and Culture's Future Explored

Updated Category News Views 136

AI's Intersection with Culture in the Spotlight Imagine a room full of people hammering out the future of AI and culture—it starts to feel like a melting pot for the mind. That was the scene in Beijing when the ICCSD Advisory Committee congregated on October 26, 2026. With experts pooling from four different countries, there was no shortage of fireworks. They hashed out...

Continue Reading
CureGene's CG-0416: Promising Weight Loss Breakthrough

Updated Category News Views 109

Game-Changer in Weight Management? Oh, the obesity world is buzzing, folks! There's some big noise coming from CureGene, and it's catching the attention of every lab-coat smarty in town. They just tossed out some preclinical data on CG-0416 at Obesity Week 2026 that could shake up how we tackle weight loss. Anyone still clinging to their old diet books might want to take...

Continue Reading
Bacterial Breakthrough in Cancer Therapy: Game Changer?

Updated Category News Views 0

Blurring Lines Between Bugs and Biotech Well, wouldn't you know it, the eggheads over at Jeonbuk National University in South Korea are at it again, pushing the boundaries of what these little bacterial buggers can do. This time, they’ve had a crack at cancer therapy, using engineered Salmonella to pack a double punch against breast cancer in mice. Now, if that ain't...

Continue Reading
Local Voices to Shape Mekong's Story in New Alliance

Updated Category News Views 307

Unpacking the New Storytelling Strategy Right off the bat, let's make it clear—this isn't just another run-of-the-mill environmental project announcement. When the National Geographic Society teams up with ThaiBev to empower Southeast Asian storytellers, they're not just waving around the usual conservation banner. Instead, they're betting on local voices to lead the...

Continue Reading

Top 5 Most Recently Viewed Articles

Future of Super Abrasives in Precision Engineering Markets

Updated Category News Views 96

Projected Growth of the Super Abrasives Market The global super abrasives market is on an exceptional growth trajectory, aiming to surpass a valuation of US$ 11.0 billion by 2032 from US$ 7.0 billion in 2023. This impressive growth, forecasted at an estimated CAGR of 6.5% from 2024 to 2032, reflects the diverse opportunities that lie ahead. Industry Drivers and...

Continue Reading
PSE&G Gains Top Spot in JD Power Rankings: What's Behind the Success?

Updated Category News Views 236

PSE&G Climbs To Number One Spot: What's Changed? Public Service Electric & Gas (PSE&G), New Jersey's largest utility, just snagged the top spot for business electric customer satisfaction in the East, according to JD Power's latest study. This is an upgrade from their second place showing in 2025. But how did they leapfrog their competition to reach the pinnacle? The...

Continue Reading
Hilbert Group Enhances Portfolio with Investment in CCD Token

Updated Category News Views 160

Hilbert Group Broadens Its Horizon with Strategic Investment Hilbert Group, a renowned global digital asset investment firm, is making waves in the blockchain space with its latest strategic long-term investment in CCD, the native token of Concordium, a cutting-edge PayFi blockchain designed for institutional-grade payments. A Landmark Move Beyond Bitcoin and Ethereum...

Continue Reading
Explore the Dynamic Features of the 2026 Ford Escape Now

Updated Category News Views 272

Discover the Exciting Evolution of the 2026 Ford Escape The all-new 2026 Ford Escape brings significant improvements in design, technology, and performance that will surely captivate new car buyers. Akins Ford, a premier Ford dealership near Atlanta, is excited to offer an in-depth look at what makes this compact SUV a standout choice for drivers. Key Design Enhancements...

Continue Reading
Forestar Group Navigates Challenges as Stock Hits New Low

Updated Category News Views 117

Forestar Group’s Stock Hits a 52-Week Low Forestar Group Inc. (NYSE: FOR) is experiencing a tough time in the current market environment. The company's shares have recently fallen to a 52-week low of $25.27. This decline highlights the struggles faced by the real estate and land development sector over the past year, contributing to a substantial 24.6% decrease in their...

Continue Reading